SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurogen (NRGN)
An SI Board Since June 1996
Posts SubjectMarks Bans Symbol
523 35 0 NRGN
Emcee:  Terry McCormick Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
223 The Motley Fool - June 17, 1999 17:27 June 17, 1999/FOOLWIRE/ -- Neuropsychiatphbolton-6/17/1999
222 It would be fun to get Waldholz and Eisinger together, in the same room. Excepscaram(o)uche-6/17/1999
221 Wall Street Journal article: interactive.wsj.com TomThomas M.-6/17/1999
220 >> his outfit was "hideous"... isn't that a plus? << scaram(o)uche-6/17/1999
219 I've met Penner and he is not a snappy dresser, but usually not awful. phbolton-6/17/1999
218 I would like to know how NRGN got the WSJ to write such a prominent piece of fNeuroInvestment-6/17/1999
217 Penner on "Bloomberg" audio with an interview on the license deal... LLCF-6/17/1999
216 Neurogen Licenses AIDD(SM) Technology to Pfizer for $27 Million This is good nphbolton-6/17/1999
215 yeah, they have continued to accumulate... almost all of the "insider&quophbolton-6/4/1999
214 I didn't realize the Tisch family was up to 20% now. Tom Thomas M.-6/4/1999
213 does this explain today's blip upward? News article received, Thursday, Jphbolton-6/4/1999
212 Neurogen Announces Second Extension of Obesity Research Program with Pfizer biThomas M.-5/12/1999
211 this seems interesting: biz.yahoo.com Date Name Action Shares Type Price Valuephbolton-4/18/1999
210 You guys are saying 95-2, when you intend to say 91-2. I think . . . Tom Thomas M.-2/6/1999
209 Thanks, Harry. Very much appreciate your comments. (eom) scaram(o)uche-2/4/1999
208 No. I was not suggesting that. I do have some doubts as to how good a predictoNeuroInvestment-2/4/1999
207 Are you suggesting that 95-2 might have proved effective in clinical trials agaHB-2/4/1999
206 Rick: Actually, in looking again at the R&D platform valuations for variouNeuroInvestment-2/3/1999
205 Any news or views to share on the obesity drug trials? Right or wrong, that isVolcano888-2/3/1999
204 Harry: >> NRGN seems overpriced even at tonight's close. << Nscaram(o)uche-2/2/1999
203 Historically I have tended to be critical of Neurogen, and have never recommenNeuroInvestment-2/2/1999
202 Harry: Yup. I was gung-ho, largely because I thought that past failures must scaram(o)uche-2/2/1999
201 There was a time (95/96) that I printed criticism of NRGN for giving away its fNeuroInvestment-2/2/1999
200 You're right- real ugly. Ritchmc-2/2/1999
199 Thoughts? Ugly. I sold some calls about a week ago, so I've been slow to scaram(o)uche-2/2/1999
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News